Back to mobile site

Jefferies: Oral Wegovy Outpacing Injectables; Lilly (LLY) Well-Positioned Ahead of April PDUFA

March 20, 2026 8:14 AM EDT Send to a Friend
Jefferies analyst Akash Tewari reiterated a Buy rating and $1,300.00 price target on Eli Lilly (NYSE: LLY)The analyst commented, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login